Back to search

Switzerland· 66831003

Mavenclad 10 mg, Tabletten

A cladribine product containing cladribinum, registered in Switzerland by Merck (Schweiz) AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L04AA40

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedMavenclad 10 mg, TablettenATCL04AA40REGISTER NO.66831003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Cladribine is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AA40 (cladribine), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Cladribine · ATC L04AA40

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cladribine costs, country by country.

Normalised to the WHO defined daily dose (0.34 mg), the median price runs from $0.048 in France to $90.83 in Switzerland — a ×1908 gap.

  • Switzerland: $90.83 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Cladribine · price per daily dose (0.34 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$90.83
  • FR France$0.048
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
cladribinum
Manufacturer
Merck (Schweiz) AG
Country
Switzerland (CH)
ATC code
L04AA40
ATC class
Cladribine
Defined daily dose
0.34 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680668310036
    Blist 6 Stk
    CHF 11367.4

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

409 interactions on record for cladribine.

Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cladribine · interactions on record

409 records

  • 326 severe
  • 79 moderate
  • 4 info

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cladribine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cladribine products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Leuject
  • Belgium · Leustatin
  • Bulgaria · Леуджект
  • Czechia · Leuject
  • Germany · Leustatin
  • Spain · Leustatin
  • Finland · Leuject
  • France · Leustatine
  • United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
  • Greece · Leustatin
  • Croatia · Leuject
  • Hungary · Leuject
  • Iceland · Mavenclad
  • Italy · Leustatin
  • Liechtenstein · Mavenclad
  • Luxembourg · Leustatin
  • Netherlands · Leustatin
  • Norway · Leuject, Mavenclad
  • Poland · Biodribin, Leuject
  • Portugal · Cladribina Generis, Leustatin
  • Romania · Leuject
  • Sweden · Leuject
  • Slovenia · Leuject

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/df053b22-41c6-4dfb-a385-02e54dbb4900
GET /v1/drugs/df053b22-41c6-4dfb-a385-02e54dbb4900?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "cladribinum 10 mg",
  "valid_from": "2023-01-01",
  "limitations": "[{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong><em>Aktive schubf&ouml;rmige remittierende Multipler Sklerose (aktive RRMS)<br></em></strong><em>Mavenclad wird verg&uuml;tet f&uuml;r die Behandlung von erwachsenen Patienten mit aktiver schubf&ouml;rmig remittierender Multipler Sklerose (MS), definiert durch klinische oder bildgebende Befunde. Behandlung durch einen Facharzt der Neurologie.</em></p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"20873.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-09-01\"},{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong>Hochaktive schubf&ouml;rmige remittierende Multipler Sklerose (hochaktive RRMS)<br></strong>Mavenclad wird verg&uuml;tet zur Behandlung von erwachsenen Patienten mit hochaktiver schubf&ouml;rmig remittierender Multipler Sklerose (MS) definiert durch klinische oder bildgebende Befunde.</p>\\n<ul>\\n<li style=\\\"list-style: none;\\\">\\n<ul>\\n<li>Bei Patienten mit hoher Krankheitsaktivit&auml;t trotz Behandlung mit einer krankheitsmodifizierenden Therapie (in der Regel w&auml;hrend mindestens 6 Monaten), oder</li>\\n<li>Bei therapienaiven Patienten richtet sich die Verg&uuml;tung nach aktuell geltenden klinischen Leitlinien wie der DGN.</li>\\n</ul>\\n</li>\\n</ul>\\n<p>Behandlung durch einen Facharzt der Neurologie mit zeitlichem Zugang zu MRI.</p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"20873.02\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-09-01\"}]",
  "galenic_form": "Tabl 10 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2019-06-01",
  "self_retention_pct": 10
}

See everything about cladribine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.